BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--Orum Therapeutics (“Orum” or the “Company”), a clinical-stage private biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals (“Vertex”) (Nasdaq: VRTX) rights to conduct research using Orum’s Dual-Precision Targeted Protein Degradation (TPD²®) technology for the discovery of novel targeted conditioning agents for use with gene editing..

波士顿和大田，韩国--（商业新闻短讯）--Orum Therapeutics（“Orum”或“公司”），一家临床阶段的私人生物技术公司，开创了降解物-抗体偶联物（DAC）领域，今天宣布了一项全球多目标许可和期权协议，授予Vertex Pharmaceuticals（“Vertex”）（纳斯达克：VRTX）使用Orum的双精度靶向蛋白质降解（TPD²®）技术进行研究的权利，以发现用于基因编辑的新型靶向调理剂。。

Following the research period for each target, Vertex will have the option to obtain a worldwide, exclusive license to research, develop, manufacture, and commercialize DACs developed with Orum’s TPD² technology for that target. Under the terms of this agreement, Orum will receive an upfront payment of $15 million and is eligible to receive additional option payments and milestones potentially totaling up to $310 million per target for up to three targets, as well as tiered royalties on potential future global annual net sales.

在每个目标的研究期结束后，Vertex将有权获得全球独家许可，以研究、开发、制造和商业化使用Orum的TPD²技术为该目标开发的DAC。根据该协议的条款，Orum将收到1500万美元的预付款，并有资格获得额外的期权付款和里程碑，每个目标最多可获得3.1亿美元，以及未来全球年净销售额的分层版税。

Vertex is responsible for all research, development, and commercialization..

Vertex负责所有的研究、开发和商业化。。

“Vertex is a leader in discovering and developing innovative medicines, including being the first to receive FDA approval of a CRISPR/Cas9 gene-edited therapy, and we are pleased they’ve selected Orum’s TPD² technology to discover novel targeted conditioning agents,' said Sung Joo Lee, Ph.D., CEO and founder of Orum Therapeutics.

Orum Therapeutics首席执行官兼创始人Sung Joo Lee博士说：“Vertex是发现和开发创新药物的领导者，包括第一个获得FDA批准的CRISPR/Cas9基因编辑疗法，我们很高兴他们选择了Orum的TPD²技术来发现新型靶向调理剂。”。

“This agreement with Vertex creates the potential to treat patients in a novel indication space with our leading targeted protein degradation approach for an exciting new therapeutic class of degrader-antibody conjugates.”.

“与Vertex的这一协议创造了在新的适应症空间中治疗患者的潜力，我们领先的靶向蛋白质降解方法可用于令人兴奋的新型降解剂-抗体偶联物治疗类别。”。

About Vertex

关于顶点

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases.

Vertex是一家全球生物技术公司，投资于科学创新，为患有严重疾病的人创造变革性药物。该公司已批准用于治疗多种慢性、缩短寿命的遗传疾病（囊性纤维化、镰状细胞病和输血依赖性β地中海贫血）的根本原因的药物，并继续推进这些疾病的临床和研究计划。

Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency..

Vertex还在其他严重疾病的一系列模式中拥有强大的临床研究治疗渠道，对因果人类生物学有深入的了解，包括急性和神经性疼痛，APOL1介导的肾脏疾病，IgA肾病，常染色体显性多囊肾病，1型糖尿病，1型强直性肌营养不良和α-1抗胰蛋白酶缺乏症。。

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For.

Vertex成立于1989年，全球总部位于波士顿，国际总部位于伦敦。此外，该公司在北美、欧洲、澳大利亚、拉丁美洲和中东设有研发基地和商业办事处。Vertex一直被公认为行业最佳工作地点之一，包括连续14年入选《科学》杂志的最佳雇主名单，以及《财富》杂志的100家最佳工作公司之一。

For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X..

有关公司更新和Vertex创新历史的更多信息，请访问www.vrtx.com或在LinkedIn、Facebook、Instagram、YouTube和Twitter/X上关注我们。。

About Orum’s TPD² Approach

关于Orum的TPD²方法

Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach builds novel targeted protein degraders combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class, tumor-selective TPDs for the treatment of cancer. Orum has developed new molecular glue degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway.

Orum独特的双精度靶向蛋白质降解（TPD²）方法构建了新型靶向蛋白质降解剂，结合抗体的精确肿瘤细胞递送机制，以产生创新的，一流的肿瘤选择性TPD，用于治疗癌症。Orum开发了新的分子胶降解剂有效载荷，可通过E3泛素连接酶途径特异性降解癌细胞内的细胞内靶蛋白。

Conjugated to antibodies, the payloads are designed to be delivered specifically to cancer cells and degrade the intracellular target protein and cause tumor cell death..

与抗体结合，有效载荷被设计为专门递送至癌细胞并降解细胞内靶蛋白并导致肿瘤细胞死亡。。

About Orum Therapeutics

关于Orum Therapeutics

Orum Therapeutics is a private, clinical-stage biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) and stabilizers (TPS²™) with the precision of antibody targeting to improve cancer treatment for more patients. The lead therapeutic candidate from the TPD² GSPT1 platform, ORM-5029, is in clinical development for the treatment of HER2-expressing solid tumors.

Orum Therapeutics是一家私人临床阶段生物技术公司，率先开发细胞特异性靶向蛋白质降解剂（TPD²®）和稳定剂（TPS²™），具有抗体靶向的精确度，可改善更多患者的癌症治疗。来自TPD²GSPT1平台的主要治疗候选物ORM-5029正在临床开发中，用于治疗表达HER2的实体瘤。

The TPS² approach uses proprietary Cbl-b inhibitor payloads conjugated to immune cell- or tumor cell-targeting antibodies. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com..

TPS²方法使用与免疫细胞或肿瘤细胞靶向抗体偶联的专有Cbl-b抑制剂有效载荷。Orum位于美国马萨诸塞州列克星敦和韩国大田。欲了解更多信息，请访问www.orumrx.com。。

Orum Therapeutics Forward-Looking Statements

Orum Therapeutics前瞻性声明

This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the potential therapeutic value of Orum’s technologies and TPD2 approach; the potential for successful completion of research and the exercise of any option; the potential for the payment of any option payments, milestones, or royalties; and the potential for clinical success for ORM-5029 are forward-looking statements.

本新闻稿包含基于Orum Therapeutics，Inc.（“Orum”）当前期望和信念的前瞻性声明。本新闻稿中关于非历史事实的声明，包括但不限于与Orum技术和TPD2方法的潜在治疗价值有关的声明；成功完成研究和行使任何选择的可能性；支付任何期权付款、里程碑或版税的可能性；ORM-5029的临床成功潜力是前瞻性的陈述。

These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; risks related to clinical trials, including potential delays, safety issues, or negative results; business decisions made by Vertex; competition from alternative therapies; the risk that product candidates may not be successfully commercialized or adopted; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, health care reform, prices, and reimbursement rates.

这些前瞻性声明基于管理层截至本发布之日的预期和假设，并受到众多风险和不确定性的影响，这可能导致实际结果与此类声明中明示或暗示的结果存在重大差异。这些风险和不确定性包括但不限于研发活动成功的不确定性；与临床试验相关的风险，包括潜在的延误，安全问题或负面结果；Vertex做出的商业决策；替代疗法的竞争；候选产品可能无法成功商业化或采用的风险；以及与关键员工的招聘和保留、波动的市场和经济状况、医疗改革、价格和报销率有关的风险。

The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release..

本演示文稿中的前瞻性声明仅在发布之日起生效，Orum不承担更新或修订任何声明的义务。Orum提醒投资者不要过于依赖本新闻稿中的前瞻性声明。。